Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

Akebia Therapeutics (AKBA) has significantly outperformed the Medical sector year-to-date, achieving a 94% return against the sector's average decline of 7.8%. This strong performance is underpinned by a Zacks Rank of #1 (Strong Buy) and a 34.4% increase in its full-year earnings consensus estimate over the last three months, signaling robust analyst sentiment. Similarly, Alignment Healthcare (ALHC) also demonstrated notable outperformance with a 22.5% YTD return and a #1 Zacks Rank.

Analysis

Akebia Therapeutics (AKBA) has demonstrated exceptional performance, delivering a 94% year-to-date return that starkly contrasts with the broader Medical sector's average decline of 7.8% and its direct Medical - Drugs industry's modest 3.6% gain. This outperformance is underpinned by strengthening fundamentals, as evidenced by a significant 34.4% upward revision in the Zacks Consensus Estimate for its full-year earnings over the past three months. This revision points to a strong improvement in analyst sentiment and earnings outlook, culminating in a Zacks Rank of #1 (Strong Buy), which suggests potential for market outperformance in the near term. For context, Alignment Healthcare (ALHC) is also highlighted as an outperformer within the struggling Medical sector, returning 22.5% year-to-date with a 5% increase in its consensus EPS estimate and a similar #1 Zacks Rank. The data indicates that despite overall sector weakness, specific companies with robust, improving earnings outlooks are being rewarded by the market.

Key Decisions for Investors

• Investors should evaluate Akebia Therapeutics' strong upward momentum, which is fundamentally supported by a significant positive revision in full-year earnings estimates and a top-tier Zacks Rank.
• Given the Medical sector's broad -7.8% year-to-date decline, a strategy focused on individual stock selection based on improving earnings outlooks, such as with AKBA and ALHC, appears more effective than broad sector exposure.
• It is critical to monitor future earnings estimate revisions for AKBA, as the current bullish thesis is heavily predicated on the continuation of these positive analyst adjustments to sustain its outperformance.
• For diversification within the outperforming segment of the Medical sector, Alignment Healthcare offers an alternative with a strong Zacks Rank and positive YTD return, though its earnings estimate revision of 5% is more modest than AKBA's.